• Mashup Score: 0

    Vorasidenib (AG-881) is a promising targeted therapy for gliomas with IDH1 or IDH2 mutations. This novel approach could potentially revolutionize glioma treatment, reducing side effects and improving outcomes. Gliomas, specifically Grade 2 gliomas, are a complex group of brain tumors with varying prognoses dependi…

    Tweet Tweets with this article
    • Exciting advancements in oncology! AG-881 (Vorasidenib) is a potential game-changer in treating #gliomas, a type of #braintumor Read our in-depth article with an interview with Karan Dixit, MD, during #ASCO23. @NorthwesternMedicine https://t.co/P7uZQ4tby4

  • Mashup Score: 0
    Program | Best of ASCO - 10 month(s) ago

    8:15 AM-9:10 AM Complimentary Continental Breakfast 8:15 AM-5:00 PM Exhibits Open 9:10 AM-9:15 AM Welcome and Chair Remarks Sonali M. Smith, MD, FASCO University of Chicago Welcome and Chair Remarks 9:15 AM-10:05 AM Gastrointestinal Cancers Sunnie S. Kim, MD University of Colorado Cancer Center Gastrointestinal…

    Tweet Tweets with this article
    • We’re excited to hear from Rimas Lukas, MD, of @LurieCancer @NUFeinbergMed, about the practice-changing INDIGO study and its implications for future #braintumor research at the upcoming Best of #ASCO23 Meeting in Seattle! View the agenda at: https://t.co/4dtOxUG3Pi #BTSM https://t.co/wpX67rkZon